Naurex's New Leaf

Why New Leaf led a $65M A round for Naurex spinout Aptinyx

With a clinically validated MOA and a broadly applicable discovery platform, the former Naurex Inc. team convinced new investor New Leaf Venture Partners to lead a tranched $65 million series A round last week for spinout Aptinyx Inc.

Aptinyx houses a

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers